How is Biotech Innovating to Treat Hemophilia? Let’s Review
Experts say hemophilia treatment is at a 'precipice of a therapeutic revolution.' From antibodies to…
Experts say hemophilia treatment is at a 'precipice of a therapeutic revolution.' From antibodies to…
Still catching up on news? We've picked out the most exciting things that happened besides…
UniQure has published clinical data revealing that its gene therapy for hemophilia B is effective…
Over 10,000 human diseases are caused by exactly one faulty gene. Gene therapy promises to fix…
Update (2/11/2017): uniQure has closed its public offering raising over $91m (€78M) on the Nasdaq, taking advantage…
uniQure is getting ready to start a Phase III clinical trial in 2018 with a…
Biotech is the best source of innovation in R&D, making its companies the darlings of…
Sander van Deventer is now a managing partner at Forbion after playing a critical role…
Following a Breakthrough Designation from the FDA earlier this year, the Dutch biotech has scored the European equivalent…
The excitement about the therapy was undercut when it became clear Glybera would be a…
Pharma would seemingly best biotech in any competition. A few CEOs explain why it left the honor…
We've compiled a list of some of the latest advances of biotech in the field…